MoneyWorks4Me

Hester Biosciences informs about press release

28 Oct 2021 Evaluate
Hester Biosciences has informed that it enclosed press release titled 'Hester Biosciences Limited Q2 and H1 FY22 Results- Revenue up by 6% and 24%, Net Profit up by 16% and 35%, for Q2 and H1 FY22 - Appointment of additional Directors on the Board'.

The above information is a part of company’s filings submitted to BSE.

Hester Biosciences Share Price

2413.65 -45.60 (-1.85%)
14-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1924.90
Dr. Reddys Labs. 1202.00
Cipla 1450.00
Lupin 2235.00
Zydus Lifesciences 1140.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: